GENELUX Corporation — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Amounts are in U.S. dollars; financial statement figures below are stated in millions unless noted. Genelux is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies. It has no products approved for sale and has not generated product-sales revenue.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0.170 | $0 |
| Research and development expense | $2.943 | $1.827 | $5.788 | $4.196 |
| General and administrative expense | $2.452 | $0.972 | $6.239 | $2.067 |
| Net loss | $5.821 | $2.820 | $16.185 | $6.621 |
| Loss per share, basic and diluted | $0.23 | $0.31 | $0.72 | $0.73 |
| Operating cash flow | Not presented by quarter | Not presented by quarter | $(10.008) | $0.417 |
- The $0.170 million six-month revenue was from shipment of previously paid-for clinical-trial product to Newsoara; it is not product-sales revenue. No gross margin or other operating margin is reported.
- At June 30, cash was $27.140 million, current assets $28.683 million, current liabilities $7.878 million, total liabilities $9.107 million, and shareholders’ equity $22.256 million. Current assets exceeded current liabilities by approximately $20.805 million.
- Cash increased $26.743 million in the first half, principally because financing activities provided $37.256 million, including IPO and private-placement proceeds. Investing activities used $0.505 million.
- Most convertible debt was converted to equity at the January 2023 IPO. At June 30, $0.065 million of shareholder convertible-note principal remained past due and payable on demand; accrued interest of $0.060 million was also disclosed. Lease liabilities totaled $1.814 million.
Changes from comparable periods and unusual items
- Q2 operating expenses rose to $5.395 million from $2.799 million; net loss increased to $5.821 million from $2.820 million. For the first half, operating expenses rose to $12.027 million from $6.263 million and net loss to $16.185 million from $6.621 million.
- Management attributed higher R&D costs primarily to clinical and regulatory work on the Phase 3 recurrent platinum-resistant ovarian cancer (PRROC) trial, employee costs, and stock compensation. Higher G&A reflected public-company legal and professional costs, insurance, hiring, and stock compensation.
- First-half other expenses included $3.110 million of financing costs related to warrants issued with converted notes, $0.402 million of debt-extinguishment costs, and $0.649 million of debt-discount amortization. The option repricing also generated $2.642 million of first-half stock-compensation cost.
- Shareholders’ equity turned positive from a $35.783 million deficit at year-end 2022, following the IPO, private placements, and conversions of preferred stock and debt. Common shares outstanding increased from 9.127 million at year-end to 25.856 million at June 30; 26.183 million were outstanding August 9.
Outlook, risks and contingencies
- Management expects June 30 cash plus $27.5 million of additional private-placement commitments to fund operations for at least 12 months. It cautions that assumptions may prove wrong and that committed funds may not all be received. The filing also states that $30 million of private-placement funding was contractually due by November 15, 2023; $2.5 million of the commitments was received after quarter-end.
- Management says existing and planned financing can support the Phase 3 PRROC trial, but will not fund registration trials in other indications or development of other candidates. Further funding will be needed; no assurance is given that it will be available on acceptable terms.
- Management expects significant and increasing operating losses and expenses as clinical development proceeds. No specific financial guidance or revenue forecast is provided. The auditor’s prior-year report included a going-concern explanatory paragraph; management now expects at least 12 months of runway based on cash and committed proceeds.
- Olvi-Vec’s Phase 3 PRROC trial is underway. A Newsoara Phase 1/2 SCLC trial in China continued after a treated patient experienced serious events, including impaired liver function and coagulation disorder; the patient recovered, and the trial continued with de-escalated dose cohorts. Management did not expect an impact on U.S. trials.
- Risks include clinical efficacy, safety and enrollment uncertainty; manufacturing comparability and supply; a national shortage of platinum-based chemotherapy that has slowed some PRROC trial enrollment; dependence on financing and collaborators; and potential dilution. Genelux reports one pending lawsuit and does not believe its outcome is reasonably likely to materially harm the business or financial results. Disclosure controls were judged effective at a reasonable-assurance level.
Important facts for investors to verify
- Whether the remaining private-placement commitments are received on schedule and whether the stated runway assumptions hold.
- Progress, enrollment, safety and results of the Phase 3 PRROC trial, including any FDA feedback on manufacturing comparability and trial design.
- Cash burn, expense growth and the amount of additional capital needed to fund trials beyond PRROC.
- The effect of the outstanding options, warrants, restricted stock units and subsequent equity issuances on future share dilution.
- Developments in the China SCLC trial, chemotherapy supply, and the pending litigation.